Poland· PL-100539350
Palsonify
A paltusotine product containing paltusotine, registered in Poland. The same ATC class is registered in 9 of our 19 countries.
Checked against URPL (Poland) on
Informational only — not a medical device.
Where it is registered
Paltusotine is registered in 9 of 19 countries.
Countries holding a registration under ATC H01CB06 (paltusotine), each read from that country’s own register.
- This record: Poland, from URPL (Poland)
- 6 of them publish a price we can compare per daily dose
Paltusotine · ATC H01CB06
9 / 19 countries
- Belgiumprice
- Czechiaprice
- Denmark
- Finlandprice
- Icelandprice
- Ireland
- Netherlands
- Polandprice
- United Statesprice
The record
At a glance
URPL (Poland)- Active substance
- Paltusotine
- Manufacturer
- —
- Country
- Poland (PL)
- ATC code
- H01CB06
- ATC class
- Paltusotine
- Reimbursed
- Not published by this register
- Source register
- URPL (Poland)
- Last checked
- September 27, 2026
Packs & prices · 0
No packs listed by the register for this record.
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same medicine, other countries
Paltusotine in 8 other countries
What each register calls a product with the same active substance — salts and hydrates count as the same.
- BelgiumPalsonify 30 mgCrinetics Pharmaceuticals Europe
- CzechiaPALSONIFYCrinetics Pharmaceuticals Europe GmbH, Amsterdam
- FinlandPalsonifyCrinetics Pharmaceuticals Europe GmbH
- IrelandPalsonify 30 mg film-coated tabletsVoisin Consulting Life Sciences
- IcelandPalsonifyCrinetics Pharmaceuticals Europe GmbH
- NetherlandsPalsonify 30 mg filmomhulde tablettenCrinetics Pharmaceuticals Europe GmbH
- SwedenPalsonify 30 mg Filmdragerad tablettCrinetics Pharmaceuticals Europe GmbH
- United StatesPALSONIFYCrinetics Pharmaceuticals, Inc.
Authorised across Europe · EMA
The same active substance is authorised in 2 EEA countries. Names it is sold under:
- Iceland · Palsonify
- Norway · Palsonify
Source: European Medicines Agency, Article 57 product data.
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of URPL (Poland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/d2c39c56-fe28-4212-9c18-7bfd7fceb993 GET /v1/drugs/d2c39c56-fe28-4212-9c18-7bfd7fceb993?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Tabletki powlekane",
"source": "urpl",
"strength": "30 mg",
"packaging": "Rp ¦ EU/1/26/2021/002 ¦ 167337\n1 butel. 60 tabl.",
"substance": "Paltusotine 30 mg",
"common_name": "Paltusotine",
"pl_product_id": "100539350",
"pozwolenie_nr": null,
"auth_procedure": "CEN",
"authorisation_validity": null
}See everything about paltusotine.
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.